Nov. 2 at 1:44 PM
$SUPN "Heads up alert! Only three days until Upcoming earnings on Tuesday, 11/4/2025 for
$SUPN
Bullish (7.5)
Supernus Pharmaceuticals (SUPN) is currently positioned as a strong contender in the specialty pharmaceuticals sector, particularly within the central nervous system (CNS) treatment space.
The company has exhibited remarkable stock performance, with a one-year total shareholder return of approximately 54%, and a notable 55% increase over the past three months alone.
This momentum is largely attributed to robust sales growth from its key products, Qelbree and GOCOVRI, which have been instrumental in exceeding revenue expectations.
The company’s P/E ratio stands at a competitive level compared to its peers, reflecting its growth potential and operational efficiency.
Moreover, analysts have noted a positive earnings surprise history for SUPN, which bodes well for future performance.
The latest earnings forecast suggests a slight decline in earnings, yet this has not dampened investor sentiment, as evidenced by recent upgrades from financial analysts, including a shift from ""Neutral"" to ""Overweight"" by Piper Sandler.
In terms of upcoming earnings reports, Supernus Pharmaceuticals is set to announce its third-quarter financial results on November 4, 2025.
Analysts are cautiously optimistic, anticipating a decline in earnings but maintaining a focus on the company’s ability to leverage its CNS drug pipeline effectively.
Historical performance indicates that SUPN has often surpassed earnings estimates, which could play a significant role in shaping market expectations.
Consensus estimates suggest a slight contraction in earnings, yet the strong sales trajectory of its flagship products may mitigate the impact of this anticipated decline.
Investors are particularly keen on how management addresses growth strategies and responds to market dynamics during the earnings call.
Overall, the specialty pharmaceuticals sector has shown resilience and growth potential, bolstered by innovative product pipelines and increasing demand for CNS-related treatments.
This sector's performance has been strong, with many companies, including Supernus, capitalizing on emerging trends and shifting consumer needs.
As such, SUPN's positioning within this landscape, coupled with its operational strengths, suggests a favorable outlook for investors.
- Funds were net buyers of
$SUPN during the previous reporting quarter.
- Funds with large holdings in
$SUPN include:
- Armistice Capital LLC, MV:
$152MM. Fund Rank: 72%
www.armisticecapital.com
- GW&K Investment Management LLC, MV:
$40MM. Fund Rank: 76%
- Rubric Capital Management LP, MV:
$22MM. New position. Fund Rank: 92%
www.rubriccapital.com
- Point72 Asset Management LP, MV:
$16MM. Fund Rank: 91%
www.point72.com
- Krensavage Asset Management LLC, MV:
$15MM. Fund Rank: 65%
www.krensavage.com
- Last 10 days performance: 9%
- Last 30 days performance: 15%
- Last 90 days performance: 55%
Some of the latest news articles:
- Title: Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Publication Date: 10/30/2025 2:00:28 PM, Source: yahoo
URL: https://finance.yahoo.com/news/analysts-estimate-amphastar-pharmaceuticals-amph-140028727.html?.tsrc=rss
- Title: 3 Cash-Producing Stocks That Fall Short
Publication Date: 10/30/2025 4:32:31 AM, Source: yahoo
URL: https://finance.yahoo.com/news/3-cash-producing-stocks-fall-043231382.html?.tsrc=rss
- Title: BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
Publication Date: 10/29/2025 9:15:01 PM, Source: yahoo
URL: https://finance.yahoo.com/news/bridgebio-pharma-bbio-reports-q3-211501816.html?.tsrc=rss
- Title: Can Supernus Pharmaceuticals Sustain Momentum After 13% Jump on Neuroscience Pipeline News?
Publication Date: 10/29/2025 5:54:40 PM, Source: yahoo
URL: https://finance.yahoo.com/news/supernus-pharmaceuticals-sustain-momentum-13-175440241.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
